To Evaluate the Treatment Effect of an Anti-Infective Agent for Complicated Infections (0826-053)

An Open-Label, Single-Arm, Non-Comparative Study to Evaluate the Efficacy, Tolerability & Convenience of Invanz(TM) (Ertapenem Sodium) In the Treatment of Community-Acquired Sepsis in Adults

To collect clinical response data with the use of ertapenem in community acquired sepsis.

Inclusion Criteria:

• Male or female patients, 18 years of age or older
• Patients present with at least two of the following signs and symptom:
• fever (temperature> 38c or < 36c)
• heart rate > 90 beats/min)
• respiratory rate> 20 breaths/min)
• high white blood cell count > 12,000/ul or >10% bands)

Exclusion Criteria:

• Patient has a history of allergy or hypersensitivity (anaphylaxis) or serious adverse reaction to ertapenem or any carbapenem
• Patient has a poor chance of survival for more than 14 days.
• Patient has an apache ii score > 15 (see attachment 3.
• Patient has an infection caused by pathogens resistant to ertapenem
• The patient requires antibiotics other than ertapenem (such as: glycopeptides, macrolides or antifungal agents)